Jasper Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
421
across all filing types
Latest filing
2026-05-21
Regulatory Filings
Country
US
United States of America
Listing
US
JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| CURRENT REPORT | 2026-05-21 | English | |
| QUARTERLY REPORT | 2026-05-14 | English | |
| CURRENT REPORT | 2026-05-14 | English | |
| SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject) | 2026-02-12 | English | |
| 4 Filing | 2026-02-10 | English | |
| SCHEDULE 13G/A Filing | 2026-01-26 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 46753000 | CURRENT REPORT | 2026-05-21 | English | ||
| 46302530 | QUARTERLY REPORT | 2026-05-14 | English | ||
| 46274504 | CURRENT REPORT | 2026-05-14 | English | ||
| 19424598 | SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject) | 2026-02-12 | English | ||
| 31723393 | 4 Filing | 2026-02-10 | English | ||
| 31723405 | SCHEDULE 13G/A Filing | 2026-01-26 | English | ||
| 13206942 | CURRENT REPORT | 2026-01-08 | English | ||
| 13206943 | CURRENT REPORT | 2026-01-07 | English | ||
| 13206944 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13206945 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13206946 | Director's Dealing 2026 | 2026-01-06 | English | ||
|
2025
4 filings
| |||||
| 13206947 | Major Shareholding Notification 2025 | 2025-12-02 | English | ||
| 13206948 | CURRENT REPORT | 2025-12-02 | English | ||
| 13206949 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13206950 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology,…
|
AIM | US | Professional, scientific and te… |
|
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and te…
|
AIMD | US | Professional, scientific and te… |
|
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, p…
|
— | CA | Professional, scientific and te… |
|
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious me…
|
AKRO | US | Professional, scientific and te… |
|
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostic…
|
NMI | DE | Professional, scientific and te… |
|
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detectio…
|
ALMR | US | Professional, scientific and te… |
|
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cel…
|
TCRT | US | Professional, scientific and te… |
|
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerativ…
|
1AI | AU | Professional, scientific and te… |
|
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing thera…
|
ALGS | US | Professional, scientific and te… |
|
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and ne…
|
ALX | CA | Professional, scientific and te… |
Jasper Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34406/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34406 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34406 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34406 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34406}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Jasper Therapeutics, Inc. (id: 34406)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.